Immunic advances MS therapy vidofludimus calcium during Q3

Immunic Inc. (NASDAQ:IMUX) reported significant progress for its oral MS treatment, vidofludimus calcium, during Q3, presenting positive clinical data at ECTRIMS from the CALLIPER and EMPhASIS studies, which demonstrated statistically significant disability improvement and sustained efficacy with a favorable safety profile. The company anticipates topline data from its ENSURE phase 3 trials in relapsing MS in 2026, while recently granted US patents strengthen commercial protection for the drug in both relapsing and progressive MS, extending exclusivity beyond 2041.

Analysis

Immunic Inc. (NASDAQ:IMUX) reported robust clinical data for its oral MS treatment, vidofludimus calcium, during Q3, highlighted by presentations at the 2025 ECTRIMS conference. The CALLIPER study demonstrated a statistically significant effect on confirmed disability improvement, while the EMPhASIS phase 2 open-label extension showed 92.3% of 254 patients free of 12-week confirmed disability worsening at 144 weeks. This long-term data underscores the drug's durability, favorable safety, and tolerability profile, with low dropout rates reinforcing patient appreciation.

The company is on track for topline data from its ENSURE phase 3 trials in relapsing MS in 2026, targeting a statistically significant outcome on the primary endpoint of time to first relapse. Complementing this clinical progress, recently granted US patents extend commercial protection for vidofludimus calcium in both relapsing and progressive MS beyond 2041. This intellectual property significantly strengthens the drug's market exclusivity and long-term revenue potential.

The combination of compelling clinical efficacy, a strong safety profile, and extended patent protection positions vidofludimus calcium as a potentially transformative oral treatment option in the competitive MS market. The upcoming Phase 3 readout in 2026 represents a critical near-term catalyst, with ongoing discussions for potential partnerships indicating strategic commercialization efforts. The overall sentiment is strongly positive, reflecting the optimistic outlook for IMUX.

Key Decisions for Investors

• Investors should closely monitor the ENSURE phase 3 trial topline data readout in 2026, as this represents a major catalyst for Immunic's valuation and potential drug approval.
• Evaluate the long-term commercial protection provided by the recently granted US patents extending exclusivity beyond 2041, which significantly enhances the drug's market potential and competitive moat.
• Assess the company's progress in securing potential commercialization partners, as successful collaborations could accelerate market penetration and de-risk future development.